Mim Neurosciences is developing new treatments for neurodegenerative disease based on NAD biology
Mim Neurosciences is developing novel small molecules targeting NMNAT2; the neuron's most important enzyme for NAD synthesis. Situated in Melbourne, Australia and within the Centre for Eye Research Australia, we are ideally located to translate findings from bench-to-bedside.
↓
Need
Treatments that arrest neurodegeneration and are neuron-specific are the Holy Grail of neurodegenerative disease research
Meet the team
Pete Williams
CEO, founder, inventor
Andrea Brancale
Medicinal chemist, inventor
Peter Hovstadius
Business development advisor
Flora Hui
Ocular translation development lead
-
![]()
Pete Williams awarded Novo Nordisk Foundation Pioneer Innovator award
Pete Williams awarded Novo Nordisk Foundation Pioneer Innovator award for further development of NMNAT2 targeted novel compounds. The award for DKK 832,650 will drive further discovery and proof of concept data.
-
![]()
Mim Neurosciences awarded Vinnova funding
Mim Neurosciences was awarded Vinnova funding (Innovativa Impact Startups Autumn 2023). The award for SEK 297,000 will help further develop the business and IP strategy.
-
![]()
New study published in Nature Communications
The research team of Pete Williams have developed new compounds targeting NMNAT2 that drive high levels of neuronal NAD and provide neuroprotection in retinal ganglion cell injury models.
